Abivax S.A.
0RA9.L
London Stock Exchange125.60
EUR
-1.20
- -
Abivax S.A.
0RA9.L
(London Stock Exchange)
Recent
price
125.60
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Abivax S.A. (Ticker: 0RA9.L) is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms through enhanced expression of microRNA-124 to modulate the immune response in patients with chronic inflammatory diseases. The company develops its lead product candidate, obefazimod (formerly ABX464), an investigational, orally administered, once-daily small molecule that enhances miR-124 expression in immune cells; obefazimod targets ulcerative colitis, with positive top-line results from Phase 3 ABTECT 8-week induction trials announced in July 2025 and 44-week maintenance data on track for Q2 2026, as well as Crohn's disease via the ongoing ENHANCE-CD trial with 12-week induction data expected in 2H 2026; Abivax explores obefazimod for additional inflammatory indications and investigates follow-on compounds from its proprietary chemical library. Founded in 2003 and headquartered in Paris, France, with a research center in Montpellier, France, and a U.S. office in the greater Boston area, the company operates primarily in Europe and the United States. Recent developments include the completion of a $747.5 million public offering in July 2025 to fund operations into Q4 2027, post-period conversions of convertible notes by Heights Capital Management and Kreos Capital, and a strategic shift from initial HIV focus to inflammatory bowel diseases following promising preclinical and Phase 2a results in ulcerative colitis.